论文部分内容阅读
随着干细胞组织工程医学的进展,干细胞移植治疗心脏疾病尤其是缺血性心脏病的研究已经积累了大量的基础研究数据,但就移植细胞选择、移植时机、移植细胞数量、移植后细胞的分化、再生能力及旁分泌作用等尚有较多争议,而对其相关分子机制及与基因组织工程、临床药物相互影响等的研究更是处于起步阶段。大量的资料表明骨髓间充质干细胞(BMSCs)在心脏再生医学中有独特优势,本文将重点讨论BMSCs移植在心脏再生医学中的研究进展,并就其与基因工程、组织工程和临床药物联合应用加以探讨。
With the advances of stem cell tissue engineering and medicine, a great deal of basic research data have been accumulated in stem cell transplantation for the treatment of heart diseases, especially ischemic heart disease. However, the selection of transplantation cells, the timing of transplantation, the number of transplanted cells, the differentiation of cells after transplantation , Reproductive ability and paracrine role are still more controversial, and its related molecular mechanisms and with the tissue engineering, clinical drug interactions and other research is in its infancy. Numerous data indicate that bone marrow mesenchymal stem cells (BMSCs) have unique advantages in cardiac regeneration medicine. This article will focus on the research progress of BMSCs transplantation in cardiac regenerative medicine and its application in combination with genetic engineering, tissue engineering and clinical medicine To explore.